Skip to content
Open access

Tregs transduced with a Ro60-reactive TCR have increased immunosuppressive functions in Sjögren’s disease

Sep 2026 · iScience · Vol 29 · 0 citations · 63 references
Medicine

Abstract

Summary Sjögren’s disease (SjD) is a T cell-driven autoimmune condition strongly associated with the HLA-DRB1∗03:01 allele and autoantibodies against the Ro60 protein. Previous studies have identified deficiencies in regulatory T cells (Treg) in patients, indicating a breakdown in immune tolerance. Current treatments remain limited to symptomatic relief or broad immunosuppression, without addressing the underlying immune dysregulation. In this study, we present the first preclinical evidence supporting a TCR-engineered Treg (TCR-Treg) therapy specifically targeting SjD. We designed a TCR-Treg that recognizes a dominant epitope of the Ro60 antigen (Ro60369-383) presented by HLA-DRB1∗03:01 and demonstrate that these cells can selectively suppress autoreactive T cells more effectively than polyclonal Treg. These findings underscore the pathogenic significance of the Ro-HLA-DRB1∗03:01 axis and provide proof-of-concept for a targeted, antigen-specific Treg therapy. This approach offers a promising strategy to restore immune tolerance and represents a potential disease-modifying treatment for genetically defined subsets of patients with SjD.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.